Solu Therapeutics Appoints A New CBO, Michael I. Boretti

Solu Therapeutics, a biotechnology company specializing in developing therapeutics to target disease-causing cells using its CyTaCTM (Cytotoxicity Targeting Chimera) platform, has appointed Michael I. Boretti, Ph.D., as Chief Business Officer (CBO).

With over 15 years of leadership experience in biotechnology, Dr. Boretti has a proven track record in company development and deal-making across various therapeutic areas. In his role as CBO, he will spearhead Solu’s business development strategy, strategic financing, and alliance management efforts.

Michael I. Boretti on the Right – New CBO

“Solu’s innovative CyTaC platform offers a novel approach to targeting previously inaccessible disease-causing cells, offering potential benefits across a wide range of medical conditions,” stated Dr. Boretti. “I am thrilled to join the dedicated Solu team to drive the development of groundbreaking medicines that can improve patients’ lives.”

Josh Alba
Josh Alba
Josh Alba stands at the forefront of contemporary business journalism, his words weaving narratives that illuminate the intricate workings of the corporate world. With a keen eye for detail and a penchant for uncovering the underlying stories behind financial trends, Josh has established himself as a trusted authority in business writing. Drawing from his wealth of experience and relentless pursuit of truth, Josh delivers insights that resonate with readers across industries.
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x